Video

CMSC 2020 Day 1: Peter Calabresi, MD, on CNS Immune Responses in Progressive MS

Author(s):

NeurologyLive® Staff

Peter Calabresi, MD, delivers the Whitaker Lecture as part of the 2020 CMSC Virtual Annual Meeting.

For more coverage from CMSC 2020, click here.

To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020, click here.

To complete the evaluation and claim credit, go to www.highmarksce.com/mscare. Create a new account or log in with your user name and password. Select the Enduring Materials tab, then select the activity from the listing and follow the instructions to complete the activity and receive your credit.

Related Videos
Paul Melmeyer, MPP (Credit: CGTLive)
Robert J. Fox, MD; Andreas Muehler, MD, MBA
Lawrence Robinson, MD
Cheryl D. Bushnell, MD, MHS, FAHA
Related Content
CBD Leads to Nonseizure Improvements, AbbVie Launches 24-Hour Levodopa Infusion in EU, CNM-Au8 Improves Visual Function and Cognition
January 13th 2024

CBD Leads to Nonseizure Improvements, AbbVie Launches 24-Hour Levodopa Infusion in EU, CNM-Au8 Improves Visual Function and Cognition

Marco Meglio
NeuroVoices: Joseph Sullivan, MD, on Exploring Antisense Oligonucleotides for Dravet Syndrome, Rare Epilepsies
September 13th 2023

NeuroVoices: Joseph Sullivan, MD, on Exploring Antisense Oligonucleotides for Dravet Syndrome, Rare Epilepsies

Joseph Sullivan, MD
Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis
July 12th 2023

Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis

Isabella Ciccone, MPH
Understanding Nuances of Mobile Stroke Units and When to Transfer Directly to Angiography: Shazam Hussain, MD, FRCP, FAHA
February 13th 2023

Understanding Nuances of Mobile Stroke Units and When to Transfer Directly to Angiography: Shazam Hussain, MD, FRCP, FAHA

M. Shazam Hussain, MD, FRCP(C), FAHA
CMSC Best Practices in Multiple Sclerosis Therapies Roundtable
November 30th 2022

CMSC Best Practices in Multiple Sclerosis Therapies Roundtable

Apitegromab Improves Quality of Life in SMA, ARB Therapy Leads to Lowered Epilepsy Risk, Donanemab Reduces Alzheimer-Related Plasma Biomarkers
October 29th 2022

Apitegromab Improves Quality of Life in SMA, ARB Therapy Leads to Lowered Epilepsy Risk, Donanemab Reduces Alzheimer-Related Plasma Biomarkers

Marco Meglio
© 2024 MJH Life Sciences

All rights reserved.